Clinical trials in Porto – page 7

498 clinical trials in Porto, Portugal across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PortugalEnsaios-Clinicos.pt

Porto at a glance

498

clinical trials

Research sites5

Quick filters

498 trials in Porto

Open in trial search

Dementia Alzheimer's type

Recruiting

Study of KarXT (trospium chloride and xanomeline tartrate) and KarX-EC (xanomeline tartrate) for cognitive impairment in mild to moderate Alzheimer's disease

Investigational

Study of KarXT (trospium chloride and xanomeline tartrate) and KarX-EC (xanomeline tartrate) for cognitive impairment in mild to moderate Alzheimer's disease

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Trospium Chloride
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Breast cancer+1

Recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Adenovirus infection

Recruiting

Comparing brincidofovir and cidofovir for treating adenovirus infection in children and adults after stem cell transplantation

InvestigationalNo placebo

Comparing brincidofovir and cidofovir for treating adenovirus infection in children and adults after stem cell transplantation

InvestigationalNo placebo

Portugal

Participants:0–17 years · 18–64 years · 65+ years
Substances:Anhydrous Cidofovir
Sponsor:Symbio Pharmaceuticals Ltd.

Contact Research Centre

Non-small cell lung cancer+1

Recruiting

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Ischaemic stroke

Recruiting

Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

Registered drugNo placebo

Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Alteplase
Sponsor:Insel Gruppe AG

Contact Research Centre

Pulmonary arterial hypertension

Recruiting

A study of LTP001 in combination with standard treatment for adults with pulmonary arterial hypertension

Investigational

A study of LTP001 in combination with standard treatment for adults with pulmonary arterial hypertension

Investigational

Portugal

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:LTP001
Sponsor:Novartis Pharma AG

Contact Research Centre

Dry age-related macular degeneration

Recruiting

Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

Investigational

Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Xelafaslatide
Sponsor:ONL Therapeutics Inc.

Contact Research Centre

Colitis ulcerative+1

Recruiting

Long-term safety study of subcutaneous vedolizumab in children and adolescents with ulcerative colitis or Crohn's disease

Registered drugNo placebo

Long-term safety study of subcutaneous vedolizumab in children and adolescents with ulcerative colitis or Crohn's disease

Registered drugNo placebo

Portugal

Participants:0–17 years
Substances:Vedolizumab
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Non-small cell lung cancer+2

Recruiting

Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

Registered drugNo placebo

Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Maia Biotechnology Inc.

Contact Research Centre

Plasma cell myeloma

Recruiting

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Daratumumab
Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Bicara Therapeutics Inc.

Contact Research Centre

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Porto

What the registry says about research in the country

01 Ophthalmology & Rare Diseases

Innovative research focusing on polypoidal choroidal vasculopathy and rare genetic conditions like PMM2-CDG, exploring new treatment approaches to improve patient outcomes.

Vision disorders
Genetic disorders
Treatment efficacy studies

02 Oncology & Hematology

Groundbreaking studies in chronic myelogenous leukemia, multiple myeloma, and advanced malignancies, including research on novel therapies for non-small cell lung cancer.

Blood cancers
Solid tumors
Immunotherapy

03 Dermatology & Immunology

Comprehensive research into conditions like hidradenitis suppurativa, plaque psoriasis, and pyoderma gangrenosum, evaluating new therapeutic approaches.

Inflammatory skin conditions
Autoimmune disorders
Novel biologics

04 Cardiology & Metabolic Disorders

Studies examining hypertrophic cardiomyopathy, familial hypercholesterolemia, and innovative treatments for obesity.

Heart conditions
Metabolic diseases
Weight management

05 Neurology & Genetic Disorders

Investigating treatments for Dravet Syndrome, menstrual migraine, and rare conditions like Niemann-Pick disease.

Neurological disorders
Rare diseases
Pain management

Back to Portugal All countries